Clinical features | Splitting | Amplification | ||
---|---|---|---|---|
Frequency | P value | Frequency | P value | |
Gender | ||||
Male | 47.2% (50/106) | 0.089 a | 86.2% (94/109) | 1.000 a |
Female | 28.6% (8/28) | 89.3% (25/28) | ||
Age | ||||
< 60 | 47.8% (33/69) | 0.274 | 87.1% (61/70) | 1.000 a |
≥ 60 | 38.5% (25/65) | 86.6% (58/67) | ||
Tumor size | ||||
T1, T2 | 50.0% (10/20) | 0.511 | 85.0% (17/20) | 0.728 a |
T3, T4 | 42.1% (48/114) | 87.2% (102/117) | ||
Lymph node metastasis | ||||
N0 | 30.2% (19/63) | 0.004 | 79.4% (50/63) | 0.022 a |
N1 | 54.9% (39/71) | 93.2% (69/74) | ||
Stage | ||||
I, IIa | 29.3% (17/58) | 0.004 | 79.3% (46/58) | 0.039 a |
IIb, III, IV | 53.9% (41/76) | 92.4% (73/79) | ||
Differentiation | ||||
G1 | 40.7% (11/27) | 0.762 b | 85.2% (23/27) | 0.118 b |
G2 | 41.7% (30/72) | 91.9% (68/74) | ||
G3 | 48.6% (17/35) | 77.8% (28/36) |